HomeACADEMIA
ACADEMIA

AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist
(May.28.2018)

Wakayama Medical University Professor Nobuyuki Yamamoto
Nobuyuki Yamamoto, deputy director of the School of Medicine, Wakayama Medical University, expressed his high hopes that AstraZeneca’s PD-L1 inhibitor durvalumab will become a new treatment option for patents with Stage III non-small cell lung cancer (NSCLC) ...
(LOG IN FOR FULL STORY)

News Calendar